TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in
A phase 1/2 trial of Darolutamide, Abiraterone acetate in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
Overview
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) is a phase 1/2 interventional study registered as NCT07190300 by Novartis Pharmaceuticals, with 181 participants planned, started 2026-01-13 and due to reach its primary completion in 2032-08-02. Interventions recorded: Tulmimetostat, Darolutamide, Abiraterone. Conditions listed: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Abiraterone acetate, Novartis, Prostate cancer.
- TrialA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Shares Abiraterone acetate, Novartis, Prostate cancer.
- TrialA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer
Shares Darolutamide, Prostate cancer.
- TrialA Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi
Shares Darolutamide, Prostate cancer.
- TrialA Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Shares Darolutamide, Prostate cancer.
- TrialStudy of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Shares Darolutamide, Abiraterone acetate, Prostate cancer.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Abiraterone acetate, Novartis, Prostate cancer.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Prostate cancer.